Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis

Cancer Immunology, Immunotherapy

Volumn 64, Issue 7, 2015, Pages 853-860

  Yu, Haiming ^a   Yang, Junlan ^a   Jiao, Shunchang ^a   Li, Ying ^a   Zhang, Wei ^b   Wang, Jiandong ^a  

^a Chinese Peoples Liberation Army General Hospital   (China)

^b 401 Hospital of PLA   (China)

Author keywords

Breast cancer; CTLA 4; Cytotoxic T lymphocyte antigen 4; Disease free survival; Overall survival

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; IPILIMUMAB; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; CELL SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR MICROENVIRONMENT; TUMOR THROMBUS; BIOSYNTHESIS; BREAST NEOPLASMS; CANCER STAGING; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CTLA-4 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84933178936     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1696-2     Document Type: Article

References (22)

1. Emens LA (2012) Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther 12:1597–1611. doi:10.1586/era.12.147
2. Koch MA, Thomas KR, Perdue NR, Smigiel KS, Srivastava S, Campbell DJ (2012) T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2. Immunity 37:501–510. doi:10.1016/j.immuni.2012.05.031
3. Yu HM, Yang JL, Jiao SC, Wang JD, Li Y (2014) TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer. J Huazhong Univ Sci Technol Med Sci 34:51–58. doi:10.1007/s11596-014-1231-2
4. Grosso JF, Jure-Kunkel MN (2013) CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunol 13:5
5. Pérez-García A, Osca G, Bosch-Vizcaya A et al (2013) Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription. Hum Immunol 74:1219–1224. doi:10.1016/j.humimm.2013.05.012
6. Greenwald RJ, Latchman YE, Sharpe AH (2002) Negative co-receptors on lymphocytes. Curr Opin Immunol 14:391–396
7. Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565–594
8. Ward FJ, Dahal LN, Wijesekera SK, Abdul-Jawad SK, Kaewarpai T, Xu H, Vickers MA, Barker RN (2013) The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol 43:1274–1285. doi:10.1002/eji.201242529
9. Sigal LH (2012) Basic science for the clinician 55: CTLA-4. J Clin Rheumatol 18:155–158. doi:10.1097/RHU.0b013e31824ea103
10. Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W, Deng B, Sun J, Shao Q, Qu X (2010) New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets 10:728–736
11. Contardi E, Palmisano GL, Tazzari PL et al (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538–550
12. Jaberipour M, Habibagahi M, Hosseini A, Habibabad SR, Talei A, Ghaderi A (2010) Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res 16:547–551. doi:10.1007/s12253-010-9256-8
13. Erfani N, Razmkhah M, Ghaderi A (2010) Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer. Cancer Invest 28:828–832. doi:10.3109/07357901003630934
14. Cimino PJ Jr, Perrin RJ (2014) Mammaglobin-A immunohistochemistry in primary central nervous system neoplasms and intracranial metastatic breast carcinoma. Appl Immunohistochem Mol Morphol 22:442–448. doi:10.1097/PAI.0b013e318294ca46
15. Huurman VA, Unger WW, Koeleman BP, Oaks MK, Chandraker AK, Terpstra OT, Roep BO (2007) Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clin Exp Immunol 150:487–493
16. Laurent S, Queirolo P, Boero S et al (2013) The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med 11:108. doi:10.1186/1479-5876-11-108
17. Simpson TR, Li F, Montalvo-Ortiz W et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695–1710. doi:10.1084/jem.20130579
18. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL (2013) Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210:1685–1693. doi:10.1084/jem.20130573
19. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1:32–42. doi:10.1158/2326-6066.CIR-13-0013
20. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466
21. Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S (2014) Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 7:203–209. doi:10.2147/OTT.S57335
22. Vonderheide RH, LoRusso PM, Khalil M et al (2010) Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 16:3485–3494. doi:10.1158/1078-0432.CCR-10-0505